{'fraction_non_alphanumeric': 0.045064377682403435, 'fraction_numerical': 0.023605150214592276, 'mean_word_length': 5.962686567164179, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetic and local toxicity studies of liposome-encapsulated and plain mepivacaine solutions in rats

The pharmacokinetics and the local toxicity of commercial and liposome-encapsulated mepivacaine formulations injected intra-orally in rats were studied. Animals were divided in groups (n = 4–6) and treated with 0.1 mL of the formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC2%EPI), 3% mepivacaine (MVC3%), and 2% liposome-encapsulated mepivacaine (MVCLUV). The results showed that the 2% liposome-encapsulated mepivacaine reduced Cmax, prolonged AUC0–∞ and t1/2 compared with 3% plain and 2% vasoconstritor-associated mepivacaine, after intraoral injection. In addition, it was also observed that liposomal mepivacaine might protect the tissue against local inflammation evoked by plain or vasoconstrictors-associated mepivacaine, giving supporting evidence for its safety and possible clinical use in dentistry.